Clinical trials: Cancer of Nasopharynx
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Surgery, Recurrent Nasopharyngeal Carcinoma
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of…
- Trial name
- NCT04425265
- Testing
- Plasma radiofrequency ablation, Electrocautery block resection
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Cancer
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
- Trial name
- NCT01312311
- Testing
- Docetaxel, Cisplatin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Samsung Medical Center
Nasopharyngeal Carcinoma
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Recurrence rate after curative treatment for locally advanced Nasopharyngeal carcinoma (NPC) is reported varying from 15% to 30% of cases, while approximately 5-11% of patients present with de novo metastatic disease.
- Trial name
- POINT (NCT04825990)
- Testing
- Pembrolizumab
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Otolaryngological Disease, Artificial Intelligence
To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) occurs at a high frequency in southern China, northern Africa, and Alaska, with a reported incidence of 30 cases per 100 000 in Guangdong Province.
- Trial name
- NCT04547673
- Testing
- rigid nasal endoscopes
- Where
- 3 sites in China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Radiotherapy; Complications
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
In the IMRT era, patients with stage II-III (AJCC8th) nasopharyngeal carcinoma achieve high local control. However, survivors are increasingly experiencing late radiation-induced toxicities.
- Conditions
- Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
- Trial name
- NCT06313450
- Testing
- de-escalated radiotherapy, conventional radiotherapy
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT04955886
- Testing
- Surufatinib(HMPL-012)
- Where
- 2 sites in China
- Volunteers
- 14 people
- Sponsor
- Fujian Cancer Hospital
Cancer of Oropharynx, Cancer of Nasopharynx
Dysphagia Assessment After Swallowing Sparing RadioTherapy
To prospectively assess post-radiation late dysphagia by using MDADI questionnaire (deglutition-related quality of life) and objective instrumental assessment by means of Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and…
- Trial name
- DASRT (NCT03448341)
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Nasopharyngeal Carcinoma, Neoadjuvant Therapy
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced…
- Conditions
- Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
- Trial name
- NeoTurbo (NCT05340270)
- Testing
- PD-1 inhibitor+GP, GP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Carcinoma
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
In this multicenter, prospective, randomized, controlled, non-inferiority Phase III clinical trial, treatment-naïve patients with nasopharyngeal carcinoma (NPC) without metastasis will be enrolled for curative radiotherapy.
- Trial name
- OART (NCT06516133)
- Testing
- Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy, Chemotherapy, Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Sun Yat-sen University
Renal Cancer, Renal Clear Cell Carcinoma
CD70-targeted immunoPET Imaging of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma…
- Conditions
- Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT06852638
- Testing
- [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and…
- Trial name
- NCT05956587
- Testing
- BL-B01D1, SI-B003
- Where
- 16 sites in China
- Volunteers
- 121 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Cancer
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC).
- Trial name
- NCT03282617
- Testing
- CD137L-DC-EBV-VAX
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
Through open-label, single-center, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Trial name
- NCT05092217
- Testing
- Tirelizumab, salvage surgery
- Volunteers
- 80 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
A total of 120 patients with pathologically confirmed locally advanced low-risk nasopharyngeal carcinoma were enrolled. They were randomly divided into two groups, with 60 patients in each group.
- Trial name
- NCT02237924
- Testing
- endostar, DDP, IMRT
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone…
- Trial name
- NCT05340491
- Testing
- Toripalimab, Chemotherapy, Intensity modulated radiotherapy
- Where
- 12 sites in China
- Volunteers
- 212 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of…
- Trial name
- NCT04736810
- Testing
- AK105, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
The goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma…
- Trial name
- NCT05772208
- Testing
- Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT
- Where
- China
- Volunteers
- 459 people
- Sponsor
- Fudan University
Head and Neck Cancer, Nasopharynx Cancer
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Cancer care for head and neck cancers is multidisciplinary and complex and knowledge on the rare ones is limited. There is a wide consensus that to support clinical research on rare cancers, clinical registries should be…
- Conditions
- Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer, Salivary Gland Cancer
- Trial name
- EURACAN (NCT05483374)
- Testing
- observation
- Where
- 10 sites in Czechia, Germany and 1 more
- Volunteers
- 13,600 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.